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a b s t r a c t
Mammalian Hedgehog (Hh) signaling relies on three Gli transcription factors to mediate Hh responses.
This process is controlled in part by a major negative regulator, Sufu, through its effects on Gli protein
level, distribution and activity. In this report, we showed that Sufu regulates Gli1 protein levels by
antagonizing Numb/Itch. Otherwise, Numb/Itch would induce Gli1 protein degradation. This is in
contrast to inhibition of Spop-mediated degradation of Gli2/3 by Sufu. Thus, controlling protein levels of
all three Gli genes by Sufu is a conserved mechanism to modulate Hh responses albeit via distinct
pathways. These ﬁndings in cell-based assays were further validated in vivo. In analyzing how Sufu
controls Gli proteins in different tissues, we discovered that loss of Sufu in the lung exerts different
effects on Hh target genes. Hh targets Ptch1/Hhip are upregulated in Sufu-deﬁcient lungs, consistent with
Hh pathway activation. Surprisingly, protein levels of Hh target Gli1 are reduced. We also found that
myoﬁbroblasts are absent from many prospective alveoli of Sufu-deﬁcient lungs. Myoﬁbroblast devel-
opment is dependent on PDGF signaling. Interestingly, analysis of the Pdgfra promoter revealed a
canonical Gli-binding site where Gli1 resides. These studies support a model in which loss of Sufu
contributes to compromised Pdgfra activation and disrupts myoﬁbroblast development in the lung. Our
work illustrates the unappreciated complexity of Hh responses where distinct Hh targets could respond
differently depending on the availability of Gli proteins that control their expression.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Hedgehog (Hh) signaling controls key steps of development in
most tissues and organs of invertebrates and vertebrates (Briscoe
and Therond, 2013; Ingham et al., 2011; Wilson and Chuang, 2010).
The unique cellular composition and morphological movement in
individual tissues require distinct modes of Hh signaling. For
example, in the mammalian neural tube and limb, Hh expression
from a localized source, such as the notochord/ﬂoor plate and the
zone of polarizing activity (ZPA), is known to exert dose-
dependent long-range signaling effects on tissue patterning. By
contrast, in several branching organs such as the lung, epithelial
Hh signaling to the mesenchyme mediates critical aspects of
epithelial-mesenchymal interactions that drive lung branching
morphogenesis. Hh signaling thus generates different outputs in
diverse tissues, which underlie cellular changes during tissue
patterning. Uncovering the whole complement of Hh targets and
how they control cellular changes in each tissue is required for
understanding the development of a given tissue. This knowledge
will also contribute to our mechanistic understanding of tissue
regeneration and repair and cancer development, in which Hh
signaling is frequently activated (Barakat et al., 2010; Bijlsma and
Roelink, 2010; Scales and de Sauvage, 2009).
The Hh pathway has been extensively studied for two decades,
culminating in a basic framework of mammalian Hh signal
transduction that depends on Gli transcription factors (Gli1-3) to
mediate Hh responses (Beachy et al., 2010; Chen and Jiang, 2013;
Eggenschwiler and Anderson, 2007; Farzan et al., 2008; Hui and
Angers, 2011; Rabinowitz and Vokes, 2012; Robbins et al., 2012;
Ryan and Chiang, 2012; Wang et al., 2007). Gli3 (and to some
extent Gli2) undergoes limited proteolysis in the absence of the Hh
ligand to produce a transcriptional repressor (Pan et al., 2006;
Wang et al., 2000). Hh signaling not only inhibits proteolysis of Gli
proteins but also promotes the conversion of Gli proteins (primar-
ily Gli2) into transcriptional activators. Gli1, like Ptch1 and Hhip, is
a transcriptional target of Hh signaling and Gli1 induction is
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believed to amplify Hh responses. The combinatorial effects of Gli
activators and repressors likely mediate graded Hh responses in
diverse tissues. In this regard, a large gap remains in our ability to
correlate Hh signaling outputs with phenotypic outcomes since it
is difﬁcult to delineate the contributions of individual Gli protein
or its processed form. This is further complicated by the differ-
ential expression and requirement of Gli proteins (Bai et al., 2004;
Bowers et al., 2012; Cao et al., 2013; Ding et al., 1998; Matise et al.,
1998) and their complex interactions in diverse tissues (Bowers et
al., 2012; Liu et al., 2012).
One of the critical events in mammalian Hh signaling involves
regulation of Gli by Suppressor of fused (Sufu), a major negative
regulator. Studies of Sufu thus provide a unique opportunity to
uncover the molecular mechanisms by which Gli proteins control
Hh signaling. Sufu can sequester Gli proteins (Barnﬁeld et al.,
2005; Ding et al., 1999; Kogerman et al., 1999; Murone et al.,
2000), regulate Gli2/3 protein levels (Chen et al., 2009; Jia et al.,
2009; Wang et al., 2010), facilitate the production of Gli repressor
and inhibit the generation of Gli activators (Humke et al., 2010;
Tukachinsky et al., 2010). Perhaps all of these actions ensure the
production of appropriate amounts of Gli activators and repressors
as well as a pertinent Gli activator/repressor ratio necessary for
tissue development and homeostasis. The relative contribution of
multiple effects of Sufu to Gli protein functions has not been
clearly delineated.
A key aspect of Hh signaling is to turn on Hh target genes
through Gli activators. In this report, we investigate how Sufu
controls Gli1 protein levels both in vitro and in vivo (lungs). These
studies not only revealed a conserved mechanism by which Sufu
controls Gli protein levels but also led to the unexpected ﬁnding
that Hh targets can exhibit different responses when the Hh
pathway is activated. We speculate that this is because different
combinations of Gli proteins are present in a particular tissue for
activating Hh targets. Thus some Gli targets are upregulated while
others are downregulated, depending on the availability of Gli
proteins that control their expression in a speciﬁc tissue. This
result reveals the complexity of Hh responses in diverse tissues
and increases our understanding of how the Sufu/Gli circuitry
controls Hh pathway activation.
Materials and methods
Animal husbandry
All mice were handled in accordance with the animal care policies
of the UCSF Institutional Animal Care and Use Committee. Null and
conditional alleles of Sufu, Ptch1LacZ (STOCK Ptch1tm1Mps/J), Dermo1Cre
(B6.1291-Twist2tm1.1(cre)Dor/J), Gli1LacZ (STOCK Gli1tm2Alj/J) and PdgfraH2B-
eGFP (B6.129S4-Pdgfratm11(EGFP)Sor/J) mice have been previously
described (Bai et al., 2002; Chen et al., 2009; Goodrich et al., 1997;
Hamilton et al., 2003; Pospisilik et al., 2010; Yu et al., 2003).
Sufuf mice harboring loxP sites ﬂanking exons 4–8 of Sufu have
been previously reported (Chen et al., 2009). Mesenchyme-speciﬁc
deletion of Sufu was achieved by generating Sufuf/–; Dermo1Cre/þ mice
through crosses between Dermo1Cre/þ; Sufuþ /– and Sufuf/f mice.
Crosses were also set up to bring Ptch1-LacZ to Sufuf/–; Dermo1Cre/þ
mice. Embryos were obtained from timed pregnancies.
Histology and in situ hybridization
Embryos were harvested at indicated time points and the
embryos or lungs were ﬁxed in 4% paraformaldehyde (PFA) in
PBS at 4 1C overnight, embedded in parafﬁn and sectioned at 6 μm.
Histological analysis and section in situ hybridization using 33P-
labeled riboprobes were performed as reported (Chen et al., 2009).
Standard molecular biology
Standard molecular biology techniques were performed as
previously described (Nagy et al., 2003; Sambrook and Russell,
2001).
Isolation of primary lung mesenchymal cells
To derive lung mesenchymal cells, mouse embryonic lungs
from wild-type (wt) and Sufuf/–; Dermo1Cre/þ embryos were
digested in 0.05% Trypsin/EDTA at 37 1C for 10 min. Cells were
then seeded into culture dishes and incubated at 37 1C for 1 h.
Cells in suspension were removed and lung mesenchymal cells
that attached to the dishes were harvested for Western blotting,
qPCR analysis or immortalization as described (Chen et al., 2009).
Cell culture, transfections, and immunoprecipitation
Wild-type and Sufu–/– mouse embryonic ﬁbroblasts (MEFs)
(Chen et al., 2009) and lung mesenchymal cells were maintained
as described (Chen et al., 2009).
HEK293T or lung mesenchymal cells were transfected with
different combinations of pcDNA3-Gli1-3xFLAG, pcDNA3-Numb-
Myc and pcDNA3-Sufu-Myc. 48 h post-transfection, cells were
lysed with IP buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris–
Cl, 1 mM EDTA) with protease inhibitor cocktail (Roche). The
lysates were cleared by centrifugation and the resultant super-
natants were bound to 15 μl FLAG M2 agarose in a 50% slurry
(Sigma) overnight at 4 1C. Beads were washed three times with IP
buffer and eluted with SDS sample buffer for Western blot
analysis. Cycloheximide (CHX) and MG132 were purchased
from Sigma.
For Western blotting, samples were run on SDS-glycine gels and
transferred to nitrocellulose membrane following standard procedures
(Sambrook and Russell, 2001). The membrane was then blocked with
Odyssey LI-COR Blocking Buffer (LI-COR), and incubated with primary
antibodies overnight. After washes in TBST (0.1% Tween 20), the blots
were incubated with IRDye 800CW–conjugated donkey anti-goat IgG,
IRDye 800CW–conjugated donkey anti-rabbit IgG, or IRDye 680LT-
conjugated donkey anti-mouse IgG (LI-COR). The signals on the
membranes were detected with the Odyssey infrared imaging system
(LI-COR). The following primary antibodies were used: rabbit anti-Gli1
(Cell Signaling, 1:1000), rabbit anti-FLAG (Sigma, 1:2000), mouse anti-
Myc 9E10 monoclonal antibody (1:100), mouse anti-α-tubulin (Sigma,
1:2000), goat anti-Gli2 (R&D, 1:1000), goat-anti-Gli3 (R&D, 1:1000),
rabbit anti-Pdgfra (Cell Signaling, 1:2000).
RNA extraction and qPCR analysis
The following primers for mouse genes were used for qPCR: Gapdh
F: 50 AGGTTGTCTCCTGCGACTTCA 30; Gapdh R: 50 CCAGGAAATGAGCTT-
GACAAAGTT 30; Ptch1 F: 50 TGCTGTGCCTGTGGTCATCCTGATT 30; Ptch1
R: 50 CAGAGCGAGCATAGCCCTGTGGTTC 30; Gli1 F: 50 CCCATAGG-
GTCTCGGGGTCTCAAAC 30; Gli1 R: 50 GGAGGACCTGCGGCTGACTGTG-
TAA 30; Numb F: 50 CGTAGCAATGCCTGTCCGTGAA 30; Numb R: 50
AGAGGCAGCACCAGAAGACTGA 30; Pdgfa F: 50 CTGGCTCGAAGTCA-
GATCCACA 30; Pdgfa R: 50 GACTTGTCTCCAAGGCATCCTC 30; Pdgfra F:
50 GCAGTTGCCTTACGACTCCAGA 30; Pdgfra R: 50 GGTTTGAGCATCTT-
CACAGCCAC 30; Pdgfrb F: 50 ACTACATCTCCAAAGGCAGCACCT 30; Pdgfrb
R: 50 TGTAGAACTGGTCGTTCATGGGCA 30; Elastin F: 50 TCCTGGGATTG-
GAGGCATTGCA 30; Elastin R: 50 ACCAGGCACTAAACCTCCAGCA 30.
shRNA-mediated gene knockdown
shRNAs were designed using the pSicOligomaker program
(Reynolds et al., 2004). Oligonucleotides encoding shRNAs were
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cloned into the pLentiLox3.7 vector. To generate lentiviral super-
natant, HEK293T cells were transfected with the pLentiLox3.7
vector carrying the insert and the packaging vectors pLP1, pLP2,
and pLP/VSV-G using Lipofectamine 2000 (Life Technologies).
Forty-eight hours post-transfection, supernatants were harvested.
Wild-type or Sufu-deﬁcient lung mesenchymal cells at 50% con-
ﬂuency were transduced with lentiviruses supplemented with
8 μg/mL polybrene. Upon reaching conﬂuency, cells were har-
vested and the lysates were analyzed by Western blotting. The
following 19-mer sequences were used for shRNA-mediated gene
knockdown: mouse Numb (NM_001136075), 50 GAAGATGT-
CACCCTTTAAA 30 and 50 GCAGACATTCCCTCAATAT 30; mouse Itch
(NM_001243712), 50 GAAGCCAAGGTCAGTTAAA 30 and 50 GTAC-
TTCTCAGTTGATAAA 30; GFP, 50 GCAGACCATTATCAACAAA 30.
Immunoﬂuorescence and microscopy
Immunohistochemistry was performed following standard
procedures (Ausubel et al., 2003). The primary antibodies used
were: goat anti-CC10 (Santa Cruz, 1:500), rabbit anti-proSP-C
(Millipore, 1:400), hamster anti-T1α (Developmental Studies
Hybridoma Bank, 1:200), mouse anti-Ki67 (BD Biosciences,
1:100), rabbit anti-phospho-Histone H3 (PH3) (Millipore, 1:200),
mouse anti-smooth muscle actin (SMA) (Sigma, 1:1000) and
mouse anti-CD31 (PECAM-1) (BD Biosciences, 1:100). PECAM-1
staining was performed using the ABC kit (Vector Laboratories).
Antibody against Ki67 required biotin-streptavidin ampliﬁcation
with the TSA kit (PerkinElmer) for optimal signal detection.
Secondary antibodies and conjugates used were donkey anti-
mouse Alexa Fluor 594 (Life Technologies, 1:2000), donkey anti-
rabbit Alexa Fluor 488 (Life Technologies, 1:2000), biotinylated
horse anti-mouse (Jackson ImmunoResearch Laboratories, 1:1000)
and DAPI (Sigma, 1:10,000).
Luciferase assays
Analysis of transcription factor binding sites on Pdgfra promo-
ters from different species was performed using ECR Browser
(Ovcharenko et al., 2004) and rVISTA 2.0 (Loots and Ovcharenko,
2004). Mouse Pdgfra promoter fragments (–2473 to –2409 and –
3027 to –1940; position zero marks the transcriptional start of
Pdgfra) were cloned upstream of the ﬁreﬂy luciferase gene in a
modiﬁed pGL-Basic vector (denoted pGL-TK), which contains a
thymidine kinase (TK) minimal promoter. The consensus sequence
of Gli binding site (GliBS) (50GACCACCCA30) within the Pdgfra
promoter was altered to 50GACTGAAGA30 or deleted by site-
directed mutagenesis. Both mutant constructs gave similar results.
These constructs were co-transfected with pRL-TK (Renilla) and
cDNA encoding Gli1 into HEK293T cells. Cells were harvested 48 h
post-transfection for analysis using the Dual Luciferase Reporter
Assay System (Promega).
Chromatin immunoprecipitation (ChIP)
MEFs stably expressing Gli1-3xFLAG and Gli2-3xFLAG were
used for ChIP analysis following established procedures (Collas,
2011; Weinmann and Farnham, 2002). ChIP was performed using
the EZ-ChIP kit (Millipore) according to the manufacturer's man-
ual. Brieﬂy, cells were cross-linked in 1% formaldehyde and the
DNA was sonicated into a range of 100–600 bp in size using a
Bioruptor sonicator (Diagenode) for 5 cycles of 30 s on/30 s off. The
extracts were precleared in BSA-blocked protein A/G beads and
incubated with antibodies or IgG control overnight. Protein A/G
beads were incubated with the lysate-antibody complex for 1 h.
After washes, the DNA was eluted and reverse-crosslinked at 65 1C
overnight. The DNA was puriﬁed and analyzed by qPCR. The
antibodies used were mouse anti-FLAG M2 monoclonal antibody
(Sigma) and normal mouse IgG (Santa Cruz).
For ChIP analysis, the following primers were used: Pdgfra
promoter F: 50 CTTGGCTAGGCACTGGCACTTGC 30; Pdgfra promoter
R: 5’ CCAGCCCAGTTCTTGCCCTGTTC 3’; β-actin promoter F 50AGAA-
GGACTCCTATGTGGGTGA 30, β-actin promoter R 50ACTGACCTG-
GGTCATCTTTTC 30.
Results
Sufu regulates Gli1 protein levels by blocking proteasome-mediated
protein degradation
Our prior studies showed that Gli1 protein levels are increased
(likely due to transcriptional activation of Gli1) in Sufu-deﬁcient
mouse embryonic ﬁbroblasts (MEFs) in contrast to the drastically
reduced protein levels of Gli2 and Gli3 (Chen et al., 2009; Jia et al.,
2009; Wang et al., 2010). Gli2 and Gli3 are subject to Spop-
mediated ubiquitination and degradation, and Sufu antagonizes
Spop function to preserve a pool of Gli2 and Gli3 (Chen et al.,
2009; Wang et al., 2010). We also demonstrated that Gli1 is
immune to Spop-mediated protein degradation (Chen et al.,
2009; Zhang et al., 2009). In this study, we revisit the issue of
whether Sufu controls Gli1 protein levels by examining Gli1 in
Sufu–/– MEFs or Sufu-deﬁcient mouse lung mesenchymal cells
(their derivation are described below) treated with proteasome
inhibitors (e.g., MG132). To our surprise, Gli1 levels were further
increased following MG132 treatment (Fig. 1A), similar to what
was observed for Gli2 and Gli3. Since Numb was previously shown
to activate the E3 ligase, Itch, resulting in Gli1 ubiquitination and
degradation (Di Marcotullio et al., 2011), we tested the idea that
Sufu stabilizes Gli1 protein by antagonizing Numb/Itch, a mechan-
ism distinct from Sufu control of Gli2/3 protein levels. We found
that Gli1 protein levels were reduced upon Numb overexpression
in cultured cells (Fig. 1B; Supplementary material Fig. S1) and Sufu
was capable of blocking Numb activity and restoring Gli1 protein
levels (Fig. 1B; Supplementary material Fig. S1). Conversely, knock-
down of Numb or Itch in Sufu-deﬁcient lung cells led to increased
Gli1 protein levels (Supplementary material Fig. S2) by eliminating
Numb/Itch-mediated Gli1 degradation. Furthermore, Sufu over-
expression decreased the binding between Numb and Gli1 (Fig. 1C;
Supplementary material Fig. S1). This suggests that Sufu controls
Gli1 protein levels by antagonizing Numb/Itch (Fig. 1D). Interest-
ingly, Drosophila Su(fu) was also capable of stabilizing Gli1 when
expressed in cultured cells (Supplementary material Fig. S3). This
supports the idea that control of Gli1 protein levels by Sufu is a
conserved mechanism.
Loss of Sufu in the mouse lung results in increased Hh signaling but
reduced Gli1 protein levels
To further validate regulation of Gli1 protein levels by Sufu
in vivo, we examined Gli1 protein in Sufu mutants. Since Sufu
mutant embryos die at 9.5 days post coitus (dpc) before major
organs develop, conditional inactivation of Sufu is required to
investigate how Sufu/Gli interactions affect Hh signaling in various
tissues. In this work, we explored tissues not previously examined
and focused on the lung. We utilized the Dermo1Cre mouse line (Yu
et al., 2003) to convert a conditional allele of Sufu (Sufuf) into a null
allele (Sufu–) in the lung mesenchyme as well as the mesenchyme
of other tissues. Sufuf/–; Dermo1Cre/þ mice are referred to as Sufu-
deﬁcient mice in this study. Sufu-deﬁcient mice died soon after
birth likely due to respiratory failure and defects in other tissues.
As a ﬁrst step toward understanding how the loss of Sufu leads to
lung defects, we examined Hh target gene expression in Sufu-deﬁcient
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lungs by reporter activity, qPCR and Western blotting (Figs. 2A–D). For
qPCR analysis of transcript levels or Western blotting, we also isolated
lung mesenchyme since Dermo1Cre selectively inactivates Sufu in this
compartment (data not shown). We found that Ptch1 reporter activity
(Figs. 2A, B) and Ptch1/Hhip mRNA levels (Fig. 2D) were increased in
Sufu-deﬁcient lungs, indicative of Hh pathway activation. Similar to
Sufu mutant embryos, Gli2 and Gli3 protein levels were reduced in
Sufu-deﬁcient lungs (Fig. 2C). To our surprise, protein levels of Gli1, a
Hh target, were reduced in Sufu-deﬁcient lungs (Fig. 2C) even though
Gli1 mRNA levels were unaltered (Fig. 2D). This result contrasts with
the expected outcome of global activation of Hh target genes, implying
that our traditional view of Hh pathway activation is oversimpliﬁed.
We also tested whether reduced Gli protein levels were also
present in other Sufu-deﬁcient tissues and found that Sufu mutant
hearts had increased Gli1 mRNA but reduced Gli1 protein levels
(Figs. 2C, D). This is in contrast to Sufu-deﬁcient neural tubes
where Gli1 activity is increased (Cooper et al., 2005; Svard et al.,
2006), likely due to transcriptional activation of Gli1. Results from
in vitro and in vivo studies on Sufu and Gli1 are consistent with a
model in which regulation of Gli1 protein levels by Sufu is a
conserved, general mechanism. This is achieved by antagonizing
Numb through Sufu; otherwise, Numb would induce Gli1 degra-
dation (Supplementary material Fig. S4). Baseline Gli protein levels
may differ in various tissues and cell lines depending on Gli1
transcript levels. We suspect that in tissues where Gli1 protein
levels are reduced in the absence of Sufu, Hh targets controlled by
Gli1 proteins could be affected.
Myoﬁbroblast development is disrupted in Sufu-deﬁcient lungs
To gain insight into how altered Hh target gene expression in
Sufu-deﬁcient lungs could impact lung development, we con-
ducted a careful phenotypic analysis of Sufu mutant lungs at
various stages of lung development (Figs. 3A–N). The phenotypes
in Sufu mutant lungs were completely penetrant and showed little
variation from animal to animal. Early patterns of epithelial
branching seemed to be established properly in Sufu-deﬁcient
lungs, leading to the correct number and positioning of lung lobes
(Fig. 3D). However, defective morphogenesis in both the epithe-
lium and mesenchyme became apparent as lung development
proceeded (Fig. 3; supplementary material Fig. S5). At birth, Sufu
mutant lungs were smaller in size and exhibited reduced branch-
ing morphogenesis associated with a compact mesenchyme
(Fig. 3N).
Somewhat surprisingly, all the major epithelial cell types
including Clara cells (CC10þ), ciliated cells (Ac-tubulinþ), pulmon-
ary neuroendocrine cells (CGRPþ), alveolar type II (SPCþ) and type
I (T1αþ) cells (Morrisey and Hogan, 2010) were properly speciﬁed
(Figs. 4C–H) in the absence of Sufu. Most mesenchymal cell types
including the bronchial smooth muscle (SMAþ) (Figs. 4K, L) and
blood vessels (PECAMþ) (Figs. 4M, N) were also properly pro-
duced. In addition, no apparent difference in the rate of cell
proliferation (Figs. 4A, B, A0; Supplementary material Fig. S6) or
cell death (Supplementary material Fig. S6) was detected in either
the epithelium or mesenchyme between wild-type and Sufu-
deﬁcient lungs during lung development.
We noticed that Sufu-deﬁcient lungs contained disorganized
saccules, raising the possibility that alveolar development could be
affected (Fig. 3N compared to 3 M). In wild-type lungs, by 18.5 dpc
(less than 24 h before birth), myoﬁbroblasts localized to the
prospective alveoli (Fig. 4I) and participated in subsequent sec-
ondary septa formation during alveolar formation. By contrast,
myoﬁbroblasts were absent from many prospective alveoli of Sufu-
deﬁcient lungs (Fig. 4J) while smooth muscle cells surrounding the
large airways or blood vessels could be detected (Figs. 4K, L).
Moreover, reduced myoﬁbroblasts in Sufu-deﬁcient lungs were
associated with reduced expression of Elastin (Fig. 4B0). This
suggests that Hh pathway perturbation in the absence of Sufu
leads to defective myoﬁbroblast maturation and migration.
Fig. 1. Control of Gli1 protein levels by Sufu. (A) Western blot analysis of lysates from
Sufu-deﬁcient (Sufuf/–; Dermo1Cre/þ) lung cells or Sufu null (Sufu–/–) MEFs treated with
MG132 to block proteasome-mediated degradation. Endogenous Gli1 protein levels
were elevated when protein degradation was inhibited in Sufu mutants. Similarly,
protein levels of transfected Gli1 were increased when Sufu was co-expressed in wild-
type (wt) MEFs. These results suggest that Sufu stabilizes Gli1 by preventing protea-
some-dependent Gli1 degradation. Note that cycloheximide was added to block new
protein synthesis in these studies. (B) Western blot analysis of lysates from HEK293T
cells expressing various combinations of Gli1, Numb, Sufu and Acp1 (control). Numb
expression resulted in reduction in Gli1 protein levels. This is consistent with previous
reports in which Numb was shown to activate the E3 ligase, Itch, leading to Gli1
ubiquitination and degradation. Numb-induced Gli1 reduction was reversed when Sufu
was co-expressed with Numb. Tubulinwas used as the loading control. (C) Western blot
analysis of immunoprecipitated Gli1FLAG from HEK293T cell lysates to test the competi-
tion between Sufu and Numb in binding to Gli1. Co-immunoprecipitated NumbMyc by
Gli1 was signiﬁcantly reduced when SufuMyc was also pulled down by Gli1. (D) A model
in which Sufu stabilizes Gli1 by inhibiting Numb-mediated protein degradation. In,
input; IP, immunoprecipitation.
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Fig. 2. Upregulation of Hh target gene expression with concomitant Gli1 protein reduction in the absence of Sufu. (A,B) β-galactosidase staining of wild-type (wt) and Sufu-
deﬁcient (Sufuf/–; Dermo1Cre/þ; Ptch1LacZ/þ) lungs to detect Ptch1 expression in lung mesenchyme. Ptch1-LacZ expression was stronger and broader in Sufumutants compared
to wt. (C) Western blot analysis of endogenous Gli1 protein levels in wt and Sufu mutant lungs. Gli1 protein levels were decreased in Sufu mutant lungs collected at various
stages of lung development. This resembles reduced protein levels of Gli2/3 in Sufu mutant lungs. Likewise, a reduction in Gli1 protein levels was also detected in Sufu-
deﬁcient hearts. (D) qPCR analysis of Ptch1 and Gli1 mRNA in wt and Sufu mutant lungs. Ptch1 and Hhip mRNA levels were elevated in Sufu mutant lungs while Gli1 mRNA
levels were unaltered. This suggests that reduced Gli1 protein levels in Sufu-deﬁcient lungs are a result of loss of Sufu and not due to changes in Gli1 transcript levels. All
values are means7standard deviation. *Po0.05; **Po0.01; NS, not signiﬁcant (unpaired Student's t-test) (n¼6 for 12.5 dpc lungs; n¼4 for 16.5 dpc lungs; n¼4 for 16.5 dpc
heart). Elevation of Hhip mRNA levels at 16.5 dpc was not statistically signiﬁcant likely due to large variations in transcript levels among different samples. Note that Sufuf/–;
Dermo1Cre/þ lungs/heart are abbreviated as Sufu–/– lungs/heart while Sufu–/– embryos represent Sufu null embryos in this ﬁgure. FL, full-length; R, repressor. Scale
bar¼100 μm for (A,B).
Fig. 3. Conditional inactivation of Sufu in lung mesenchyme. (A-N) External morphology (A, B), dissected lungs (C, D, I, J) and histology (E-H, K–N) of lung sections fromwild-
type (wt) and Sufuf/–; Dermo1Cre/þ mouse embryos at various embryonic stages and postnatal (p) day 0 as indicated. More than 50 Sufu mutants were examined. The
phenotypes in Sufu mutant lungs were completely penetrant and showed little variation from animal to animal. Epithelial and mesenchymal development was defective in
Sufu mutants, resulting in a smaller sized lung with a compact mesenchyme. The length of the proximal-distal axis of Sufu mutant lungs is 80% of that of wt lungs. Sufu
mutant mice cannot expand their lungs and died a few hours after birth. Early patterns of epithelial branching appeared to be established properly in Sufu-deﬁcient lungs,
leading to the correct number and positioning of lung lobes. Epithelial branching at later stages of development was not as extensive in Sufu-deﬁcient lungs compared to that
in wt lungs. dpc, days post coitus. Scale bars: (K–N) 50 μm.
C. Lin et al. / Developmental Biology 392 (2014) 324–333328
Defective myoﬁbroblast development in Sufu-deﬁcient lungs is
associated with reduced PDGF signaling
We ﬁrst investigated potential perturbations of major signaling
pathways in the absence of Sufu. The expression patterns and
levels of components in the Fgf, Bmp and Wnt signaling pathways
were similar between wt and Sufu mutant lungs (Figs. 4O–T and
data not shown). We then focused on PDGF signaling since it has
been shown to play a central role in myoﬁbroblast development.
Pdgf ligand or Pdgf receptor α (Pdgfra) knockout mice die without
Fig. 4. Disruption of myoﬁbroblast development in Sufu-deﬁcient lungs. (A–Z) Immunostaining (A–N, Y, Z) and in situ hybridization (O–X) of wild-type (wt) and Sufu-
deﬁcient (Sufuf/–; Dermo1Cre/þ) lungs. No apparent difference in cell proliferation rate (judged by Ki67 and PH3 staining) or cell death was found between wt (A) and Sufu
mutant (B) lungs. Quantiﬁcation of cell proliferation in the epithelial and mesenchymal compartments at 12.5 dpcwas shown in A0 . Major epithelial cell types, including Clara
cells (CC10þ) (C, D), alveolar type II (SPCþ), type I (T1αþ) cells (E, F) and pulmonary neuroendocrine cells (CGRPþ) (G, H) were properly speciﬁed in the absence of Sufu. Most
mesenchymal cell types such as the bronchial smooth muscle (SMAþ) (K, L) and blood vessels (PECAMþ) (M, N) were also properly generated. By contrast, myoﬁbroblasts
(white arrow; marked by smooth muscle actin [SMA] staining) were greatly reduced in Sufu mutant lungs (I). This was associated with decreased Pdgfra expression (pink
signal) (compare V to U) while Pdgf ligand expression was unaltered (compare X to W). In addition, the expression patterns and levels of Shh (O, P), Fgf10 (Q, R) and Bmp4 (S,
T) or other components in Hh, Fgf and Bmp signaling were similar between wt and Sufu mutant lungs. Both Gli1 and Pdgfra were detected in the secondary septa of alveoli
(arrows in Y, Z). (B0) qPCR analysis of Pdgfa, Pdgfra, Pdgfrb and Elastin mRNA in wt and Sufu mutant lungs. PdgframRNA levels were reduced in Sufu mutant lungs while Pdgfa
and Pdgfrb mRNA levels were unaltered. This is consistent with results from in situ hybridization. Elastin transcript levels were also reduced in Sufu mutant lungs, consistent
with defective myoﬁbroblast development. All values are means7standard deviation. *Po0.05; **Po0.01; NS, not signiﬁcant (unpaired Student's t-test) (n¼3). (C0)
Western blot of endogenous Pdgfra protein levels in wt and Sufu mutant lungs. Pdgfra protein levels were decreased in Sufu mutant lungs collected at various stages of lung
development. This was likely due to reduced Pdgfra transcript levels in Sufu mutant lungs. dpc, days post coitus. Scale bars: A–F and K–N, 50 μm; G–J and Y–Z, 50 μm; O–X,
100 μm.
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myoﬁbroblasts or secondary septa (Bostrom et al., 1996; Sun et al.,
2000). We surmised that defective myoﬁbroblast development in
Sufu-deﬁcient lungs is caused by reduced PDGF signaling. To test
this idea, we examined the expression of Pdgf ligand and receptor
in wild-type and Sufu-deﬁcient lungs by in situ hybridization, qPCR
and Western blotting. We found that while Pdgfa expression was
indistinguishable between wild-type and Sufu-deﬁcient lungs
(Figs. 4W, X and B0), Pdgfra expression was drastically reduced in
Sufu mutant lungs (Figs. 4U, V and B0). By contrast, Pdgfrb
expression was unaltered in Sufu-deﬁcient lungs (Fig. 4B0). This
suggests that disrupted Hh signaling in Sufu mutant lungs leads to
reduced Pdgfra expression and consequently defective myoﬁbro-
blast development.
Pdgfra is a direct transcriptional target of Gli1
We investigated the molecular mechanisms by which loss of
Sufu leads to reduced Pdgfra expression. Since a reduction in Pdgfra
expression in Sufu-deﬁcient lungs is associated with decreased
Gli1 protein levels (despite global Hh pathway activation) and the
expression of Pdgfra and Gli1 overlaps along the alveolar wall
(Figs. 4Y, Z) and the secondary septum (arrows in Figs. 4Y, Z), we
speculate that Pdgfra could be a direct target of Gli1. Indeed, we
identiﬁed a canonical Gli-binding site (GliBS) in the mouse Pdgfra
(but not Pdgfrb) promoter (Fig. 5A). A GliBS was also found in a
similar location of the Pdgfra promoter in several vertebrate
species (Fig. 5A). This is consistent with our model in which Gli1
controls Pdgfra expression. Reduced Gli1 protein levels in Sufu-
deﬁcient lungs could contribute to compromised Pdgfra promoter
activation. By contrast, other Hh targets controlled by Gli2 and Gli3
are activated.
We further tested this idea by performing reporter assays using
Pdgfra-luc in which a Pdgfra promoter fragment is placed upstream
of the luciferase (luc) reporter (Fig. 5B). Gli1 was co-transfected
with Pdgfra-luc in MEFs and tested for its ability to activate Pdgfra-
luc. A Pdgfra fragment in which the canonical Gli-binding site is
mutated (denoted as PdgfraΔGliBS) was used as a control (Fig. 5B).
We showed that the addition of Gli1 increased Pdgfra-luc activity
but failed to activate PdgfraΔGliBS-luc (Fig. 5B). By contrast, Gli2
has low activity in activating the Pdgfra promoter in vitro (Supple-
mentary material Fig. S7). Finally, Hh stimulation led to increased
expression levels of Pdgfra but not Pdgfrb in lung mesenchymal
cells (Supplementary material Fig. S8), suggesting a connection
between Hh and PDGF signaling.
To determine whether the endogenous Pdgfra promoter is
occupied by Gli1, we performed chromatin immunoprecipitation
(ChIP) analysis (Weinmann and Farnham, 2002) on MEFs expres-
sing FLAG-tagged Gli1 and Gli2. Cell lysate from lung mesenchy-
mal cells was immunoprecipitated using FLAG antibodies. We
ampliﬁed Pdgfra genomic regions using FLAG immunoprecipitates
and found signiﬁcant enrichment of Gli1 (but not Gli2) on the
Pdgfra genomic fragment (Fig. 5C). These results suggest that
Pdgfra is a direct target of Gli1.
Fig. 5. Gli1 and regulation of Pdgfra promoter activity. (A) Sequence analysis of the Pdgfra promoter from different species. A conserved canonical Gli-binding site (GliBS) is
boxed and colored. The numbers represent distances from the transcriptional start site of Pdgfra, which is marked as position zero. (B) Schematic diagram depicting Pdgfra-
luc reporter constructs in which mouse Pdgfra promoter fragments are placed upstream of ﬁreﬂy luciferase (luc). A canonical GliBS is present in the Pdgfra promoter and is
mutated in the control construct PdgfraΔGliBS-luc (abbreviated as ΔGliBS-luc in the ﬁgure). Addition of Gli1 activated Pdgfra-luc and not PdgfraΔGliBS-luc in cell-based assays.
Control nuclear protein Smurf did not induce Pdgfra-luc expression. (C) Gli1 but not Gli2 occupied the Pdgfra promoter by ChIP analysis using MEFs expressing FLAG-tagged
Gli1 and Gli2. Gli-binding on the Pdgfra promoter was normalized to the β-actin control promoter. All values are means7standard deviation. *Po0.05; NS, not signiﬁcant
(unpaired Student's t-test) (n¼3). (D) A model of differential regulation of Gli proteins by Sufu. Loss of Sufu results in reduced protein levels of all three Gli proteins.
Reduction in Gli2/3 protein levels is associated with increased Gli activators and reduced Gli repressors. This would lead to overall Hh pathway activation and Hh target gene
expression. By contrast, reduced protein levels of the constitutive activator Gli1 result in downregulation of Hh targets that primarily rely on Gli1 for their expression such as
Pdgfra in the lung.
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Discussion
In this study, we discover that Sufu stabilizes Gli1 protein levels
by antagonizing Numb/Itch-mediated protein degradation.
Together with previous work that demonstrates control of Gli2/3
protein levels by Sufu (Chen et al., 2009; Jia et al., 2009; Wang et
al., 2010), our new ﬁnding indicates that regulation of Gli protein
levels by Sufu is a major general mechanism in modulating Hh
responses. Interestingly, our analysis of Sufu-deﬁcient lungs led to
the unexpected observation that while canonical Hh targets such
as Ptch1 are upregulated, Pdgfra, a direct target of Gli1, is down-
regulated. We propose that Hh targets do not respond uniformly
to Hh signaling under different genetic perturbations and this
could also vary from tissue to tissue. We speculate that this may be
due to differential levels of individual Gli proteins that control
common and distinct sets of Hh targets in a given tissue (Fig. 5D).
As a result, some Hh targets are activated while others are
concomitantly downregulated. Perhaps this enables Hh signaling
to generate complex outputs by regulating the availability of
different Gli proteins. Testing and generalizing this hypothesis in
diverse tissues will signiﬁcantly increase our understanding of
how Hh signaling leads to diverse phenotypic consequences in
homeostasis and disease.
Control of Gli protein levels by Sufu
It was previously reported that Sufu controls protein levels of
Gli2 and Gli3 by antagonizing Spop-mediated ubiquitination and
degradation (Chen et al., 2009; Wang et al., 2010). In addition,
Drosophila Su(fu) also controls protein levels of Ci (Gli homolog)
by antagonizing HIB/roadkill (Spop homolog) (Zhang et al., 2006).
However, Gli1 is immune to Spop-mediated regulation (Chen et al.,
2009; Zhang et al., 2009). In this study, we showed that Sufu
counters the effects of Numb/Itch-mediated Gli1 protein degrada-
tion. Thus, control of Gli protein levels by Sufu is a conserved
mechanism employed to modulate Hh responses.
It is unclear how two regulatory circuitries were evolved to
differentially control Gli1 and Gli2/3 protein levels mediated by
Sufu respectively. In this regard, it is interesting to note that
Drosophila Su(fu) not only can substitute for mammalian Sufu and
partially restore Gli2/3 protein levels in cell-based assays (Chen et
al., 2009), it is also able to stabilize Gli1 protein levels in a similar
assay. This suggests that a similar interface of molecular interac-
tions may exist between Sufu-Spop and Sufu-Numb. Alternatively,
ﬂy Su(fu) may not have exploited the Numb-Itch pathway for
controlling Ci protein levels.
Gli1 is part of a positive feedback loop of Hh responses since
Gli1 is an early transcriptional target of Hh signaling. Control of
Gli1 protein levels by Sufu may provide a mechanism to dampen
Hh signaling when Sufu becomes inactive either by Hh signaling or
in disease states. Reduced Gli1 protein levels due to loss of Sufu
would limit transcriptional activity mediated by Gli1. This resem-
bles Sufu's effects on Gli2/3 protein levels, part of which are
reﬂected by the failure to maximally activate Hh signaling in the
absence of Sufu (Chen et al., 2009; Liu et al., 2012). In considering
the consequence of loss of Sufu on Gli1 protein levels in various
tissues, it is important to take into consideration Gli1 transcription.
For instance, Gli1 is transcriptionally activated in the neural tube
when the Hh pathway is activated (e.g., loss of Sufu). We surmise
that increased Gli1 transcript levels in the neural tube would offset
the effect of Gli1 protein degradation due to loss of Sufu; as a
result, Gli1 protein levels are elevated. By contrast, transcriptional
activation of Gli1 in the lungs is not as prominent and thus Sufu-
deﬁcient lungs have reduced Gli1 protein levels. However, we
cannot rule out the possibility that different tissues may have
distinct rates of Gli1 degradation and this could also contribute to
variations in Gli1 protein levels in diverse tissues.
Epithelial-mesenchymal Hh signaling and lung development
Sufu-deﬁcient lungs display overall upregulation of Hh signal-
ing, resulting in a smaller lung with a compact mesenchyme.
Somewhat surprisingly, the rate of cell proliferation during early
lung development does not seem to be altered. Moreover, despite
defective lung development in the absence of Sufu, all major lung
cell types are properly speciﬁed. We postulate that abnormal
mesenchymal development in the absence of Sufu disrupts
epithelial-mesenchymal interactions, leading to defective epithe-
lial branching. Consequently, lung size is reduced. Uncovering the
cellular and molecular basis of lung defects in Sufu mutants would
require future studies that employ tools such as live imaging and
whole-genome analysis. This would allow the identiﬁcation of
potential defects in cellular behaviors and genes and pathways
involved in this process.
Control of PDGF signaling and myoﬁbroblast development
Removal of Sufu in the lung mesenchyme results in a reduced
number of myoﬁbroblasts. This could contribute to defective lung
development and even perinatal lethality. Alveolar myoﬁbroblasts
play a key role in alveolus formation. They are contractile cells
found in the alveolar interstitium during lung development and
possess morphological and biochemical features intermediate
between ﬁbroblast and smooth muscle. Alveolar myoﬁbroblasts
appear to be derived from a population of mesenchymal cells that
express the PDGF receptor. These cells subsequently spread to the
walls of prospective terminal saccules to become future alveolar
myoﬁbroblasts. Alveolar myoﬁbroblasts produce Elastin and parti-
cipate in septal formation during alveologenesis. Indeed, reduced
myoﬁbroblasts in Sufu-deﬁcient lungs are associated with reduced
expression of Elastin.
We showed that Sufu-deﬁcient lungs have reduced Pdgfra
expression. Since PDGF signaling plays an essential role in myoﬁ-
broblast development, our ﬁndings are consistent with the idea
that downregulation of Pdgfra expression in Sufu mutant lungs
likely results in a reduced myoﬁbroblast number. Importantly, we
demonstrated that Pdgfra is a direct target of Gli1. This allows us to
propose a model in which reduced Gli1 protein levels in the
absence of Sufu contribute to impaired Pdgfra expression and
consequently myoﬁbroblast development. Consistent with these
observations, it was previously reported that Pdgfra is regulated by
Gli1 in Hh-responsive cell lines (Xie et al., 2001). We also showed
that Gli1 and Pdgfra co-localize extensively in the alveolar struc-
ture in postnatal lungs, further supporting the notion that Gli1
regulates Pdgfra expression. Future genetic studies that employ
Sufu and Pdgfra mutants will further support a functional connec-
tion between Hh and PDGF signaling.
Possible distinct and overlapping targets of Gli proteins
Whole genome ChIP-on-chip studies using FLAG-tagged Gli1
and Gli3 in neural tissues and the limb have identiﬁed a signiﬁcant
number of genes with bona ﬁde Gli-binding sites (Vokes et al.,
2007, 2008). These studies will serve as a guide for similar efforts
in other organs such as the lungs. We anticipate that different sets
of Gli targets will be identiﬁed in various tissues. A key issue is to
determine whether certain Hh targets are controlled by distinct Gli
proteins. Certain Hh targets may possess unique binding
sequences that can only be recognized by a particular Gli protein.
Alternatively, all Gli-binding sites are degenerate and can recruit
any Gli proteins. In this case, differential binding would be an
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outcome of different Gli protein levels. Isolation of distinct cell
types from a given tissue for whole-genome ChIP analysis may
provide an opportunity to further test these hypotheses.
Gli2 is active in Sufu mutants despite its low levels. However,
Gli2 activator fails to elevate Pdgfra expression levels in Sufu-
deﬁcient lungs. Gli1 mutants are viable (Park et al., 2000) and do
not seem to display apparent defects in myoﬁbroblast develop-
ment (data not shown). Reduced Gli1 protein levels thus are
unlikely the sole cause of defective myoﬁbroblast development
in Sufu-deﬁcient lungs. Instead, loss of Sufu likely perturbs other
processes, which in conjunction with reduced Gli1 protein levels,
lead to the disruption of myoﬁbroblast development. However, it
remains possible that reduced Gli2/3 activator levels in the
absence of Sufu also contributes to reduced Pdgfra expression in
the developing lungs although Gli2 is not detected on the Pdgfra
promoter by ChIP analysis using MEFs (Fig. 5C). In this scenario,
myoﬁbroblast defects would be observed in mice deﬁcient in
multiple Gli proteins. Genetic studies that produce mice deﬁcient
in Sufu and one or multiple Gli proteins will be informative in
revealing the regulation of Gli proteins by Sufu in the lung.
Taken together, our studies highlight the complexity of regulat-
ing Gli protein functions in diverse tissues. They also form the
basis of further studies to investigate howmultiple Gli proteins are
regulated at multiple levels to control the expression of a unique
set of Hh targets in a given tissue.
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